Academic highlights ‘heterogeneous effects’ of R&DTI reform proposals

Tax

Firm age and maturity are not the same thing, one academic says, as she targets the “heterogeneous effects” of the government’s R&DTI reforms and potential alternatives.

18 November 2026 • By Carlos Tse • 4 minutes read
Share this article on:

The government’s Treasury Laws Amendment (Tax Reform No. 4) Bill 2026 introduces reforms to the Research and Development Tax Incentive (R&DTI), with one academic saying that the reforms create heterogeneous effects across innovation firms.

In a working paper, RMIT University associate professor of finance and the deputy head of the finance department, My Nguyen, stressed that while these reforms would increase support for some younger R&D-intensive firms, they “restrict access to refundable tax offsets for many firms beyond their first ten years of operation, or 15 years for therapeutic-goods R&D”.

With these changes proposed to apply from 1 July 2028, they have important implications for deep-tech and other research-intensive companies that experience long commercialisation periods, Nguyen said.

These proposed reforms will “raise offset rates for core R&D by 4.5 percentage points while removing eligibility for supporting R&D activities, lift the turnover limit for refundable offsets from $20 million to $50 million, and limit refundability to a company’s first ten years, or 15 years for therapeutic-goods R&D”, Nguyen said.

“Research-intensive companies with long commercialisation horizons may lose access to refundable federal R&D support at approximately the same stage at which expanding employment increases their exposure to state payroll taxation.”

“The reforms therefore create heterogeneous effects across innovative firms. Young firms undertaking predominantly core research may receive greater support. Firms with turnover between $20 million and $50 million could also benefit from access to refundable offsets if they satisfy the relevant age requirements. Conversely, older but still pre-profit R&D-intensive companies outside the therapeutic-goods sector could experience a substantial reduction in cash support.”

Thus, Nguyen said that the government must consider whether taxation unintentionally discourages the transition from startup to scale-up.

 
 

“These costs may be particularly consequential for innovative firms that require substantial investment and employment well before they become profitable,” she said in her paper.

“The policy challenge is to ensure that intellectual property developed within the state is accompanied by subsequent investment, employment and commercial activity. Support could therefore increasingly focus on firms making the transition from research validation to commercial production.”

Finally, Nguyen stressed that firm age and firm maturity are not the same thing.

“This is particularly relevant to deep-technology companies, where lengthy development periods are intrinsic to the innovation process. A ten-year-old software company and a ten-year-old quantum or advanced-materials company may occupy very different stages of commercial development.” 

Nguyen said that one option that the government could take is “targeted payroll tax relief for qualifying R&D-intensive growth companies”. 

“Targeted payroll tax relief for R&D-intensive scale-ups, combined with stronger commercialisation support and systematic monitoring of firm growth and relocation, represents one possible approach.”

“Such relief could be limited by firm age, R&D intensity, employment growth or expenditure on highly skilled Victorian employees. A carefully designed scheme could reduce the marginal cost of expanding innovative employment without providing a general payroll tax concession to all firms.”

Accountants DailyWant to see more stories from trusted news sources?
Make Accountants Daily a preferred news source on Google.
Tags: